Cassava Sciences (SAVA) Stock Price, News & Analysis

Company Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key Stats

• Today's Range: $2.05 to $2.17
• 50-Day Range: $1.75 to $2.70
• 52-Week Range: $1.15 to $42.20
• Volume: 547,139 shs
• Average Volume: 794,894 shs
• Market Capitalization: $102.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $54.50
• Consensus Rating: Moderate Buy

Cassava Sciences Stock Analysis - MarketRank™

Cassava Sciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 263rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cassava Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cassava Sciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cassava Sciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cassava Sciences has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.00% of the outstanding shares of Cassava Sciences have been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 10.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cassava Sciences does not currently pay a dividend.

Dividend Growth

Cassava Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.82

Percentage of Shares Shorted

13.00% of the outstanding shares of Cassava Sciences have been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 10.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 6 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cassava Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Cassava Sciences is held by insiders.

Percentage Held by Institutions

Only 38.05% of the stock of Cassava Sciences is held by institutions.

SAVA Stock Analysis - Frequently Asked Questions

How have SAVA shares performed this year?

Cassava Sciences' stock was trading at $2.36 at the start of the year. Since then, SAVA shares have decreased by 10.2% and is now trading at $2.12.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.48) EPS for the quarter.

When did Cassava Sciences' stock split?

Shares of Cassava Sciences split before market open on Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were payable to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

Who are Cassava Sciences' major shareholders?

Cassava Sciences' top institutional investors include Ground Swell Capital LLC (0.04%). Insiders that own company stock include Eric Schoen and James William Kupiec.
View institutional ownership trends.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SAVA
• CIK: 1069530
• Web: www.cassavasciences.com
• Phone: (512) 501-2444
• Fax: 512-501-0414
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cassava Sciences: $54.50
• High Price Target: $107.00
• Low Price Target: $2.00
• Potential Upside/Downside: +2,470.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.72%
• Return on Assets: -72.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.08
• Quick Ratio: 9.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.03 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 48,310,000
• Free Float: 47,149,000
• Market Cap: $102.42 million
• Optionable: Optionable
• Beta: -2.05